Syndicated article · via feeds.content.dowjones.io

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals